Class IV Medical Device Licence Pathway

1. Key takeaways

Class IV is the highest risk class in Canada. The MDL application fee is 30,713 CAD (effective from 2026-04-01), the highest tier among the four device classes. The application must present sufficient clinical data together with the risk argumentation, and Health Canada’s official examples include the artificial heart and cardiac pacemakers. Everything that applies to the lower classes applies here with greater weight: the clinical evidence must withstand the deepest review, the amendment fees are the highest in the schedule, and the post-market oversight environment is correspondingly the most intensive. A Class IV project should therefore be planned as the fullest expression of the Canadian pathway, with the classification rules, the budget and the post-market design all addressed before the submission clock starts.

• Class IV is the highest risk class; the MDL application fee is 30,713 CAD from 2026-04-01.
• The application must submit sufficient clinical data and risk argumentation.
• Official examples include the artificial heart and cardiac pacemakers.
• Amendment fees are tiered, and the non-manufacturing significant change tier is the highest of any class.
• Post-market oversight is the most intensive of the four classes and should be designed before submission.

2. Legal basis

The table below lists the sources for the Class IV pathway: the current application fee, the two-tier amendment fees, the official examples, the clinical effectiveness requirement, and the escalation rule in Schedule 1 that places devices touching the central systems into Class IV.

3. Expert insights

Insight 1: The classification rules for Class IV operate as enumerated escalations.

Under rule 1(2) of Part 1 of Schedule 1, a surgically invasive device that is intended to diagnose, monitor, control or correct a defect of the central cardiovascular system, the central nervous system, or the intrauterine fetus falls into Class IV. Rule 6(2) contains a similar escalation: where a process changes the chemical composition in a way that may introduce potentially hazardous extraneous substances, the device falls into Class IV. Between them, these two rules decide the classification of a batch of interventional and blood-processing products. The practical lesson is that Class IV membership is often determined by an escalation clause rather than by general reasoning, so the classification review should work through the enumerated rules deliberately instead of stopping at the first plausible fit.

Insight 2: The amendment fee for non-manufacturing significant changes is the highest across the four classes.

The Class IV amendment fee for a non-manufacturing significant change is 16,251 CAD (from 2026-04-01), higher than Class III’s 11,369 CAD and Class II’s 331 CAD. In a Class IV project, the cost of change management is a substantive budget item in its own right, not a rounding error. Indications, labelling architecture and software behaviour — changes that have nothing to do with the factory — are precisely the changes that land in this expensive tier, and a project that ignores this reality will find its post-approval budget consumed by the first significant revision.

Insight 3: The gap between the Class IV and Class III application fees is close to double.

Class III is 14,163 CAD; Class IV is 30,713 CAD. The gap reflects the difference in review depth. When enterprises plan the pathway, the classification boundary determination should be done solidly: the difference between a Class III and a Class IV conclusion is not an administrative nuance but a near-doubling of the entry cost, together with the deeper clinical expectations that come with the higher class. A careful classification analysis, checked against the escalation rules, is the cheapest work in the entire project relative to what it protects.

Insight 4: Post-market oversight intensity is likewise highest for Class IV.

Health Canada’s official explanation states that it continuously evaluates the expected benefits and changing risks of licensed devices using scientific literature, device problem reports, information shared by international regulatory authorities, feedback from healthcare professionals and users, information requested from manufacturers, and other available information. Class IV products should have denser post-market surveillance arrangements designed in from the start. The data flows that feed this continuous evaluation — problem reports, professional feedback, manufacturer submissions — should be treated as an operating capability the company must have ready, not as a response assembled after the first incident.

4. Practical recommendations

• During classification, focus the review on the escalation clauses in Schedule 1 (rule 1(2), rule 6(2) and similar provisions).
• Build the budget from the 30,713 CAD application fee, the two amendment tiers (4,470 / 16,251 CAD), and the MDSAP cost.
• Prepare the clinical data to the highest review expectations, leaving no gap to be filled by follow-up requests.
• Establish a mechanism in change management that assesses the applicable fee tier before a change is implemented, so the cost is not discovered after the fact.
• Design the post-market surveillance plan in parallel with the submission; do not wait until the MDL has been obtained.

5. Verification checklist

• □ The escalation clauses of Schedule 1 have been reviewed and the Class IV determination is confirmed
• □ The application fee (30,713 CAD) and both amendment tiers have been budgeted separately
• □ The clinical data have been prepared to the highest review intensity
• □ A mechanism for assessing the fee tier before each change has been established
• □ The post-market surveillance plan has been designed in parallel
• □ The MDSAP certificate is valid, with Canada included in the audit scope

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com